Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in Hope-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation, and hyperbaric therapy. The acquisition is expected to be accretive to revenue and EBITDA for NRx and Hope.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Psychedelic: Compass, GH Research, MindMed report quarterly earnings
- NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
- NRx Pharmaceuticals files patent application for proprietary IV ketamine NRX-100
- NRx Pharmaceuticals awarded filing fee waiver by FDA for NRX-100 application
- Psychedelic: Enveric, Filament Health report earnings results